Lumiradx crp test achieves ce marking

London, jan. 11, 2022 /prnewswire/ -- lumiradx (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced its c-reactive protein (crp) test has achieved ce marking. the lumiradx crp test is a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of c-reactive protein with results within four minutes.
LMDX Ratings Summary
LMDX Quant Ranking